Artivion (AORT) Q1 2026 earnings review
NEXUS Approval Eclipsed by Growth Miss and Guidance Cut
Artivion's Q1 delivered a mixed narrative. The company secured FDA PMA approval for the NEXUS Aortic Arch System ahead of expectations and quickly exercised its $135M option to acquire Endospan. However, the core business stumbled: revenue of $116.3M (+12% in constant currency) missed management's expectations due to unspecified 'transient factors.' This weakness forced management to lower their newly issued FY26 guidance, cutting both revenue and Adjusted EBITDA targets. While On-X valves and Preservation Services posted strong year-over-year gains, the crucial Stent Graft segment showed significant deceleration compared to its torrid 2025 pace. Despite solid Adjusted EBITDA expansion (+26% to $22.1M), the guidance cut shifts the narrative from flawless pipeline execution to near-term commercial execution risk.
🐂 Bull Case
The early FDA approval of NEXUS allows Artivion to acquire Endospan, securing a product aimed at a $150M US market. Alongside AMDS and the future Arcevo LSA, Artivion is building a monopolistic portfolio in aortic arch solutions.
Despite the topline miss, Adjusted EBITDA grew 26% to $22.1M. Management continues to deliver on their commitment to grow bottom-line profitability faster than revenues.
🐻 Bear Case
Lowering full-year revenue and EBITDA targets immediately after setting them in Q4 suggests unforeseen operational headwinds. Management cited 'transient factors,' but the lack of specificity breeds uncertainty.
Stent Grafts, previously the primary growth engine fueled by the AMDS launch, slowed to 10% constant currency growth in Q1, down sharply from the 20-30% growth rates seen throughout 2025.
⚖️ Verdict: ⚪
Neutral. The strategic acquisition of Endospan and the early NEXUS approval are massive long-term wins. However, the sudden guidance cut and decelerating stent graft sales raise red flags about near-term commercial momentum.
Key Themes
FY26 Guidance Cut Signals Commercial Friction
Management lowered FY26 revenue guidance to $480-$496M (from $486-$504M) and Adjusted EBITDA to $100-$107M (from $105-$110M). This represents a decelerating outlook, dropping the constant currency growth expectation from 10-14% down to 7-11%. The company vaguely blamed 'transient factors' for missing Q1 expectations, leaving investors blind to whether the issue is supply chain, competitive pressure, or hospital spending delays.
Endospan Acquisition Triggers Next Growth Phase
A major catalyst was unlocked: Endospan received US FDA PMA approval for the NEXUS Aortic Arch System ahead of schedule. Artivion immediately exercised its option to acquire Endospan for $135M upfront (net of loans). While NEXUS sales will be 'negligible' in 2026 as the company builds inventory and navigates Value Analysis Committees, it secures a massive long-term revenue driver targeting a $150M annual US market, setting the stage for a January 2027 commercial launch.
Stent Graft Growth Decelerating
Stent Graft constant currency growth decelerated sharply to 10% in 26Q1, a stark contrast to the 19%, 22%, and 31% rates reported in the first three quarters of 2025. This raises critical questions about the AMDS commercial rollout in the US. The initial surge from hospital stocking orders may be fading, demanding closer scrutiny on actual sell-through and implant volume.
On-X Valve Sustains Momentum
The On-X mechanical heart valve remains a highly stable growth engine, posting 20% GAAP (17% constant currency) growth. Management noted it continues to take market share from both mechanical and bioprosthetic valves, capitalizing on strong clinical data favoring its use in patients under 65.
Currency Provides a Minor Macro Tailwind
While foreign exchange was a headwind or neutral factor for much of the prior year, management explicitly noted that currency is expected to represent an 'approximate one percentage point tailwind for the full year' in 2026.
Other KPIs
Accelerating compared to 25Q1 ($17.5M), an increase of 26%. Despite the topline miss, Artivion is executing on its strategy of growing EBITDA at roughly twice the rate of revenue, driving operating leverage and expanding margins.
Stable. Gross profit was $75.4M on $116.3M in revenue. This is a slight improvement from the 64.2% margin reported in 25Q1, reflecting a continued favorable product mix shift toward higher-margin On-X and Stent Graft sales in the US, alongside the normalization of Preservation Services.
Reversing the trend from a year ago. Revenue grew 23% YoY, but this must be contextualized: the comparable period (25Q1) suffered a severe 23% decline due to a lingering backlog caused by a November 2024 cybersecurity attack. The current result represents a stabilization rather than true organic acceleration.
Guidance
Decelerating outlook. Lowered from the initial $486-$504M range provided just a quarter ago. The new range implies 7% to 11% constant currency growth compared to FY25 adjusted revenue, a step down from the 13% CC growth achieved in FY25.
Decelerating outlook. Lowered from the $105-$110M range. Implies 12% to 20% growth over FY25, missing the company's long-stated structural goal of growing Adjusted EBITDA at twice the rate of revenue (given the 7-11% revenue guidance). Notably, this excludes ~$8M in expected Endospan-related integration expenses.
Stable expectation. Despite the early FDA approval, management expects zero meaningful US revenue from NEXUS in FY26. The year will be dedicated to building inventory and navigating hospital Value Analysis Committees (VAC) for a planned January 2027 commercial launch.
Key Questions
Unpacking the 'Transient Factors'
What specific 'transient factors' caused the Q1 revenue miss? Were these issues related to supply chain constraints, hospital staffing shortages, or pushback on pricing from hospital administration?
Stent Graft Deceleration
Stent Graft constant currency growth slowed to 10% in Q1. Is this a reflection of AMDS initial stocking orders normalizing, or are you facing friction in converting new hospital accounts and driving actual implants?
Endospan Deal Financing
With the Endospan acquisition closing for $135 million upfront, how is this transaction being financed, and where does net leverage stand post-close? How will the $8M in integration expenses impact free cash flow generation for the remainder of the year?